The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Incyte Corp

Nasdaq: INCY
Last

(U.S.) $71.57

Today's change+1.99 +2.86%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
 

Incyte Corp

Nasdaq: INCY
Last

(U.S.) $71.57

Today's change+1.99 +2.86%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.

Incyte Corp up sharply

Incyte Corp closed up sharply Wednesday, rallying (U.S.)$1.99 or 2.86% to (U.S.)$71.57. Shares have lost 5.31% over the last five days, but have gained 41.36% over the last year to date. This security has outperformed the S&P 500 by 27.27% during the last year.

Key company metrics

  • Open(U.S.) $69.57
  • Previous close(U.S.) $69.58
  • High(U.S.) $72.00
  • Low(U.S.) $69.57
  • Bid / Ask-- / --
  • YTD % change+41.36%
  • Volume444,363
  • Average volume (10-day)1,398,106
  • Average volume (1-month)1,498,210
  • Average volume (3-month)1,352,190
  • 52-week range(U.S.) $40.30 to (U.S.) $80.78
  • Beta1.07
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.37
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
S&P TSX0.10%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1981009097
Total other revenue--------
Total revenue1981009097
Gross profit198999097
Total cost of revenue0000
Total operating expense128126113113
Selling / general / administrative39413738
Research & development89857675
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income70-26-23-16
Interest income (expense), net non-operating-11-11-11-9
Gain (loss) on sale of assets--------
Other--------
Income before tax59-37-34-43
Income after tax59-37-34-43
Income tax, total0000
Net income59-37-34-43
Total adjustments to net income--------
Net income before extra. items59-37-34-43
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items59-37-34-43
Inc. avail. to common incl. extra. items59-37-34-43
Diluted net income59-37-34-43
Dilution adjustment----00
Diluted weighted average shares189168165162
Diluted EPS excluding extraordinary itemsvalue per share0.31-0.22-0.21-0.26
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.31-0.22-0.21-0.26